FDA draft guidelines suggest route to approval for early-stage Alzheimer's drugs

Share this article:
Residents refused meds, tried to flee secure unit since talking to surveyor, nursing home charges
Residents refused meds, tried to flee secure unit since talking to surveyor, nursing home charges

The Food and Drug Administration issued draft guidance Thursday on clinical trials for early-stage Alzheimer's drugs.

Alzheimer's disease involves subtle changes in the brain and few overt symptoms in its early stages. Therefore, choosing clinical trial participants and measuring whether a drug treatment results in improved feeling or function can be difficult.

Measuring levels of biomarkers such as β-amyloid and tau proteins has emerged as one way to track the progress of the disease. However, the FDA notes a lack of “widespread evidence-based agreement in the research community that an effect on a particular biomarker is reasonably likely to predict clinical benefit.”

The agency will therefore not consider biomarkers a primary outcome measure in clinical trials. However, the agency says it is “open to considering” biomarker levels as a secondary outcome measure, in conjunction with a primary clinical change. The FDA urged drug developers to conduct biomarker analysis, saying it is open to changing its guidelines.

Share this article:

More in News

Also in the news for Sept. 30, 2014 . . .

CMS clarifies appropriate use of power strips in long-term care resident rooms ...GAO: Integrating Medicare and Medicaid may not reduce costs on dual-eligible care ... Brookdale discriminated against worker with fibromyalgia, EEOC claims ... State standards for physician access under Medicaid managed care vary widely, ...

More programs drop out of Pioneer ACO pilot

The Pioneer Accountable Care Organization program is now down to 19 programs, out of an original 32, worrying those who have pushed for skilled nursing facilities to embrace the concept.

Elderly with complicated grief benefit from targeted program, study says

Complicated grief is an under-recognized problem in the elderly, but a specific treatment can help, a new study says.